Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Wuxi Apptec CO Ltd (OP: WUXIF ) 3.780 UNCHANGED Last Price Updated: 1:03 PM EDT, Sep 10, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Wuxi Apptec CO Ltd Week In Review: ImmuneOnco Out-Licenses Two Antibodies In $2 Billion Deal August 03, 2024 Shanghai ImmuneOnco Biopharma out-licensed global rites (ex-China) for two of its antibodies to Instil Bio of Dallas, Texas. ImmuneOnco will receive an upfront and near-term payments of $50 million,... Via Talk Markets Week In Review: Foreseen Sells ADC Rights To France's Ipsen In $1 Billion Deal July 13, 2024 In other news, Sichuan Biokin Pharma has filed for an IPO on the Hong Kong Exchange; more on the Biosecure Act being pushed by US Speaker of the House Johnson. Via Talk Markets Topics Initial Public Offering Exposures Securities Market Week In Review: Sciwind, Sino Biological And Biocytogen Announce Deals May 11, 2024 Beijing’s Sino Biological completed its $48 million acquisition of Vancouver-based SignalChem Biotech. Additionally, Biocytogen Pharmaceuticals signed a TCR-mimic antibody evaluation and potential... Via Talk Markets Week In Review: AriBio Sells China Rights To Alzheimer’s Candidate In $770 Million Deal March 30, 2024 South Korea’s AriBio out-licensed China rights for AR1001, an Alzheimer’s disease candidate, in an agreement worth up to $770 million. The company acquiring the asset asked to remain anonymous because... Via Talk Markets Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities March 23, 2024 Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility. Via Talk Markets Week In Review: Under Pressure From US Congress, WuXi AppTec Resigns From BIO March 16, 2024 BIO, the global lobbying organization for biotechnology firms, forced WuXi AppTec to leave the group due to pressure from the US Congress. Also, Boehringer Ingelheim acquired an option to license drug... Via Talk Markets Top 7 Biotech Winners Of Novo Nordisk, Eli Lilly's Outsourcing Strategy For Weight-Loss Drugs: Goldman Sachs March 13, 2024 Goldman Sachs analysts identified a substantial opportunity in the manufacturing sector for new obesity therapeutics, as demand for these treatments escalates. Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
